PAPE |
|
Vaxjo ID |
230 |
|
Vaccine Adjuvant Name |
PAPE |
|
Adjuvant VO ID |
VO_0005673
|
|
Description |
A novel COVID-19 vaccine adjuvant combining alum microgel with squalene to form an emulsion that enhances humoral and cellular immunity |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
alum-stabilized Pickering emulsion (PAPE) |
|
Structure |
Raspberry-like oil/water emulsion stabilized by alum microgels; cationic surface; high surface area |
|
Appearance |
Emulsion droplets (micron-sized); stable up to 120 days at 4–37°C |
|
Storage |
Stable at 4°C, 25°C, and 37°C; no leakage or aggregation observed after 120 days |
|
Preparation |
Single-step sonication using alum microgel and FDA-approved squalene; optimized at 2 mg/mL alum concentration |
|
Function |
alum is packed on the squalene/water interphase is packed, forming an alum-stabilized Pickering emulsion (PAPE). "Inheriting" from alum and squalene, PAPE demonstrates a good biosafety profile. |
|
Safety |
Well-tolerated in mice; no signs of cytokine storm, tissue damage, or organ pathology; good biosafety profile |
| References |
Peng et al., 2020: Peng S, Cao F, Xia Y, Gao XD, Dai L, Yan J, Ma G. Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. Advanced materials (Deerfield Beach, Fla.). 2020; 32(40); e2004210. [PubMed: 32864794].
|
